HIV Prevention Service Use Study in Washington DC
Part of Infections clinical trials.
This study looks at how people in the Washington, DC area use HIV prevention services. It focuses on those who are HIV-negative and either new to PrEP, taking daily PrEP pills, or getting long-acting injectable PrEP.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have tested negative for HIV (confirmed)
- You live in the Washington, DC area
- You are either new to PrEP, currently taking daily PrEP pills, or receiving long-acting injectable PrEP
- You can speak and read English
- No signs of liver problems (hepatotoxicity)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people who receive HIV care in Washington, DC and people using HIV prevention medicines (like PrEP) to understand health needs and outcomes over time. It may help improve how HIV care and prevention are delivered in local clinics.
This study is for people who are HIV-negative and want to take PrEP (a daily pill that prevents HIV). It will help researchers learn more about how to best support people taking PrEP in real-world settings.
This study is for cis-gender men who are HIV-negative and at risk for HIV. It tests a program to help you start and stay on PrEP (medication to prevent HIV).
This study looks at how taking PrEP (medicine to prevent HIV) affects HIV prevention and how much it costs in real life. You may be able to join if you are HIV-negative and are interested in starting, currently using, or have used PrEP before.
This study helps connect young people aged 13–24 to PrEP, a daily pill that prevents HIV. It tests whether offering PrEP in clinics or community locations makes it easier for you to get and stay on this prevention medication.
This study tests how to better support HIV prevention for people who inject drugs and are newly starting PrEP (medicine to prevent HIV). It focuses on people taking medication for opioid use disorder and who have mild thinking and memory problems, to help them stay safe and adhere to prevention.
Hear when a new Pre-exposure Prophylaxis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.